LIPO is "A Biotech About to Bloom"
David Moskowitz, of Standard & Poor's The Outlook, says Liposome (LIPO) is a biotech stock about to bloom. The company is a leader in using liposomal technology (chemicals trapped in fat molecules) to lower drug toxicity. Abelcet, the firm's first product, treats systemic fungal infections while Evacet, a liposomal form of the widely used anticancer agent doxorubicin, is now under FDA review. "We anticipate a positive recommendation, which should lead to approval by year-end," Moskowitz says. "If given the green light, Evacet will be sold in the billion dollar breast cancer drug market."
Moskowitz says Liposome is the right kind of biotech drug company -- "one with late-stage or currently marketed products entering large markets where therapeutic improvements are needed." Liposome is already past the arduous and failure-ridden development stage, and the return on investment at this stage is much closer. He goes on to say that late-stage companies are prime acquisition targets for larger drug companies.
"With solid management, a proven technology platform and favorable news expected, the shares have significant upside potential," Moskowitz says, adding that a potential takeover adds to the stock's "speculative appeal." |
